STING1 and prostate carcinoma: The combination of the carboplatin with STING agonist and PD-1 blockade significantly prolonged the survival of these mice.118 Similarly, STING agonists such as ADU-S100 (also known as MIW815 or ML RR-S2 CDA), 2′3′-c-di-AM (PS) 2 (Rp, Rp), and cyclic di-GMP could enhance the therapeutic efficacy of anti-PD-1/PD-L1 immunotherapy in colon cancer, HPV+ oral cancer, pancreatic cancer, prostate cancer and so on.119–121